Monrovia-based Xencor, the developer of antibody technology which is headed by Dr. Bassil Dahiyat, said today that it has received a second, milestone payment from Boehringer Ingelheim. Financial details and amount of the payment were not disclosed. The firm said the payment came due to regulatory submissions to being a Phase 1, clinical trial of a novel monoclonal antibody using Xencor's XmAb antibody engineering technology. Boehringer Ingelheim and Xencor inked their development deal in February of 2007 for the use of Xencor's technology; Xencor also has similar deals with Amgen, MorphoSys, Pfizer, Centocor, and others. Xencor is venture backed by HealthCare Ventures, MedImmune Ventures, Merlin Nexus, Novo Nordisk, Oxford Bioscience Partners, Stafford Investments, and Zen Investments.
Top NewsWednesday, April 4, 2012
Xencor Gets License Payment From Boehringer Ingelheim